Alphyn Biologics, a clinical-stage dermatology company developing multi-target therapeutics, announced positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a topical therapeutic for mild-to-moderate...
Read MoreOver four out of 10 physicians and six out of 10 patients are not satisfied with the level of control achieved for moderate to severe adult patients treated with high...
Read MoreAn online model for follow-up care of atopic dermatitis that gave patients direct access to dermatologists resulted in equivalent clinical improvement compared to patients who received traditional in-person care. There are (more…)
Read MoreRegeneron Pharmaceuticals, Inc., and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic (more…)
Read More
